New Delhi: Medanta announced on Monday (December 19) that it had appointed the former Director of All India Institute of Medical Sciences (AIIMS), Randeep Guleria, as the Chairman of the Institute of Internal Medicine and Respiratory & Sleep Medicine and Director – of Medical Education.
Dr Naresh Trehan, Medanta Chairman and Managing Director, welcomed Randeep to the Medanta family and stated, “The appointment of a senior and experienced doctor like Dr Randeep Guleria reflects Medanta’s commitment to always offering the highest standard of clinical care by our team of highly accomplished and veteran clinical faculty.”
During the pandemic, he became a household name due to Dr Guleria’s overall contribution to the nation’s COVID-19 response efforts and advice and tips to people on how to remain safe. Dr Guleria is widely known for pioneering work in lung cancer, COPD, asthma, sleep disorders, and respiratory muscle functions.
He has been published in Indian and international journals and contributed to scores of chapters in various prominent books.
The former Director of AIIMS, Delhi, was also instrumental in setting up a dedicated Department of Pulmonary Medicine and Sleep Disorders at the premier medical institute. He served in AIIMS for three decades.
From Indira Gandhi Medical College (IGMC), Shimla, Dr Guleria completed his MBBS. An academician and researcher had done MD, General Medicine and DM in Pulmonary Medicine from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh.
Dr Randeep has been awarded the Padma Shri and Dr BC Roy Award. He is associated with the World Health Organisation (WHO) on immunisation and influenza vaccination as a member of its Scientific Advisory Group of Experts (SAGE).
After serving AIIMS for 30 years, Dr Randeep Guleria has taken voluntary retirement. On September 23, his five-and-a-half-year tenure as the Director of AIIMS ended, after which he applied for VRS. On March 24, his tenure was supposed to end but was extended by three months and was extended by a further three.
